AltruBio Inc. announced that president and chief executive officer Judy Chou, Ph.D., will present an in-person corporate overview at the BIO CEO & Investor Conference taking place February 14-17, 2022 in New York, NY.
SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that president and chief executive officer Judy Chou, Ph.D., will present an in-person corporate overview at the BIO CEO & Investor Conference taking place February 14-17, 2022 in New York, NY.
Dr. Judy Chou’s presentation will highlight recent company developments, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:
Presenter: Judy Chou, Ph.D., President and CEO
Date: February 14, 2022
Location: Marriott Marquis, New York, NY
Registration: Here
In-person company presentations, educational sessions, and BIO One-on-One Partnering meetings will be held on February 14-15, 2022, with additional educational sessions and partnering live-streamed for virtual attendees on February 16-17.
ABOUT ALTRUBIO INC.
AltruBio is a privately held biotechnology company headquartered in San Francisco that is focused on developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. The company has leveraged its deep understanding of the role PSGL-1 plays as an immune checkpoint regulator protein to develop a platform for T-cell mediated immunological diseases. Its lead molecule, neihulizumab (AbGn-168H), an immune checkpoint agonist antibody targeting PSGL-1/CD162 has achieved proof of mechanism in four autoimmune and inflammatory diseases and is currently prioritized for further clinical development in steroid refractory acute graft-versus-host disease (SR-aGVHD). The company also has a number of next-generation PSGL-1 antibodies at the preclinical stage. Its lead preclinical candidate, leiolizumab (AbGn-268), has demonstrated high potency making it suitable for subcutaneous administration and is advancing toward IND for autoimmune and inflammatory disorders.
ABOUT BIO
BIO is the world’s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Subscribe to Good Day BIO.
Note on Forward-Looking Statements
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.
Contacts
AltruBio Inc:
+1-415-655-6603
+886-2-2627-2707
info@altrubio.com
Media Contact:
Darren Opland, PhD
LifeSci Communications
+1-646-627-8387
darren@lifescicomms.com
